Previous 10 | Next 10 |
AN2 Therapeutics Inc. (ANTX) is expected to report $-0.63 for Q3 2023
License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in partnership with University of Georgia Chagas expert using non dilutive f...
Enrollment Ongoing in Phase 3 Part of 2/3 Pivotal Trial of Epetraborole in Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
2023-10-04 11:58:18 ET More on AN2 Therapeutics AN2 Therapeutics prices $70.0 million stock offering Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics Financial information for AN2 Therapeutics For f...
Grant from Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant...
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ...
2023-08-23 02:29:19 ET More on AN2 Therapeutics AN2 Therapeutics started at Oppenheimer at outperform on promise of antibiotic Seeking Alpha’s Quant Rating on AN2 Therapeutics Earnings data for AN2 Therapeutics For further details see: AN2 Therapeu...
2023-08-16 03:53:28 ET More on AN2 Therapeutics AN2 Therapeutics secures $17.8M contract from NIH AN2 Therapeutics started at Oppenheimer at outperform on promise of antibiotic For further details see: AN2 Therapeutics prices $70.0 million stock offering
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares ...
2023-08-11 13:35:21 ET AN2 Therapeutics press release ( NASDAQ: ANTX ): Q2 GAAP EPS of -$0.81. R&D expenses increased for the quarter compared to the same period during 2022 due to increased clinical trial expenses, among others. For further details see: AN2 ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...
Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...